Woods Lori L
Division of Nephrology and Hypertension, L463, Oregon Health and Science Univ., 3181 S.W. Sam Jackson Park Rd., Portland, OR 97239-3098, USA.
Am J Physiol Regul Integr Comp Physiol. 2006 Oct;291(4):R1069-75. doi: 10.1152/ajpregu.00753.2005. Epub 2006 Apr 27.
Maternal glucocorticoids have been postulated to play an important role in prenatal programming for adult hypertension in the offspring. However, we have shown previously that offspring hypertension caused by maternal dexamethasone subcutaneous administration at 100 microg x kg(-1) x day(-1) can be accounted for by the corresponding reduction in food intake that these mothers experience. The present studies were designed to determine whether there is a lower dose of dexamethasone that does not reduce maternal food intake yet still causes hypertension in the adult offspring. Pregnant rats were treated with subcutaneous dexamethasone at 50 (D50) or 25 (D25) microg x kg(-1) x day(-1) on days 15-20 of pregnancy. An additional group was untreated or received vehicle injections (control). D25 and D50 dams reduced their food intake by 17% during and after treatment and gained 31% less weight than control over the course of gestation. In adulthood ( approximately 21 wk), chronically instrumented male offspring of D50 and D25 had normal blood pressures (D50: 131 +/- 2 mmHg and D25: 127 +/- 3 mmHg vs. 127 +/- 2 mmHg in control). Qualitatively similar results were found in female offspring. Thus neither dexamethasone per se at these doses nor the accompanying modest reductions in maternal food intake and weight gain have blood pressure programming effects. As far as has been tested, there does not appear to be a dose of dexamethasone that, given over this time period in the rat, programs offspring hypertension without reducing maternal food intake and weight gain. These data do not support the hypothesis that maternal glucocorticoids program offspring hypertension directly.
母体糖皮质激素被认为在后代成年高血压的产前编程中起重要作用。然而,我们之前已经表明,母体以100微克×千克⁻¹×天⁻¹的剂量皮下注射地塞米松所导致的后代高血压,可以由这些母体相应减少的食物摄入量来解释。本研究旨在确定是否存在较低剂量的地塞米松,其不会降低母体食物摄入量,但仍会导致成年后代患高血压。在妊娠第15 - 20天,对怀孕大鼠皮下注射50(D50)或25(D25)微克×千克⁻¹×天⁻¹的地塞米松。另一组未接受治疗或接受溶剂注射(对照组)。D25和D50组的母鼠在治疗期间及之后食物摄入量减少了17%,在整个妊娠期体重比对照组少增加31%。在成年期(约21周),D50和D25组长期植入仪器的雄性后代血压正常(D50:131±2 mmHg,D25:127±3 mmHg,对照组为127±2 mmHg)。在雌性后代中也发现了定性相似的结果。因此,这些剂量的地塞米松本身以及随之而来的母体食物摄入量和体重增加的适度减少都没有血压编程效应。就目前所测试的情况而言,在大鼠的这个时间段内,似乎不存在这样一种地塞米松剂量,即它能在不降低母体食物摄入量和体重增加的情况下使后代患高血压。这些数据不支持母体糖皮质激素直接导致后代高血压的假说。